We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture outline
- Bacterial vaccines in late stage development with the potential to reduce AMR
- Clostridioides difficile infection (CDI): A significant unmet medical need
- Vaccines with the potential to prevent CDI
- C. difficile toxoid vaccines in development
- Pfizer’s bivalent toxoid vaccine
- Pneumococcal disease: A continuing global medical need
- PCVs (with extended serotype coverage) under development
- Group B Streptococcus (GBS)
- GBS maternal vaccines can be administered to pregnant women
- GBS vaccines in development
- Bacterial vaccines in early-stage development with the potential to reduce AMR
- Escherichia coli
- An E.coli vaccine could protect across multiple ages that are at risk
- E. coli mechanisms of pathogenesis and vaccine action
- E. coli vaccines in development
- Shigella
- Various approaches to shigella vaccine design
- Shigella vaccines in development
- Acinetobacter baumannii
- Pseudomonas aeruginosa
- P. aeruginosa: Vaccine development
- Mycobacterium tuberculosis
- M. tuberculosis: Vaccine development
- Non-typhoidal Salmonella (NTS)
- NTS: Vaccine development
- Staphylococcus aureus
- S. aureus: Vaccine development
- S. aureus vaccines in development
- Global mobilization actions utilizing vaccines against AMR
- The Davos Declaration
- Barriers to maximizing licensed vaccine use in fighting AMR
- Barriers to maximizing vaccine use
- Efforts towards better utilization of vaccines against AMR
- Better utilization of vaccines against AMR: Efforts and future prospects
- Conclusions
- Thank you!
Topics Covered
- Vaccines in late-stage development with a potential to reduce AMR
- Vaccines in early-stage development with a potential to reduce AMR
- Global mobilization actions utilizing vaccines against AMR
- The Davos Declaration
- Barriers to maximizing licensed vaccine use in fighting AMR
- Efforts towards better utilization of vaccines against AMR
Links
Series:
Categories:
Therapeutic Areas:
External Links
- CDC 2019 AR Threats Report
- ClinicalTrials.gov database of privately and publicly funded clinical studies
- Affinivax vaccine pipeline overview
- Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants
- Biovac and PATH partnership to develop novel vaccine against newborn infection
- Path factsheet on GBS and the development of a vaccine against GBS
- Vaccinesforamr Acinetobacter baumannii pathogen profile
- WHO global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics
- CDC fact sheet on drug-resistant nontyphoidal salmonella
- Mayoclinic Staphylococcus information guide
- WHO: Common misconceptions about vaccines and immunisations
- CDC: Vaccine safety
- CDC measles cases and outbreaks information page
- WHO: Polio outbreak in the Philippines
- One shot to stop Group B Streptococcus
Talk Citation
Anderson, A.S. (2021, July 28). Vaccines and the fight against antimicrobial resistance 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/LILS6311.Export Citation (RIS)
Publication History
Financial Disclosures
- Annaliesa S. Anderson is an employee of Pfizer Inc. and may hold stock or stock options.
Vaccines and the fight against antimicrobial resistance 2
Published on July 28, 2021
40 min
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Annaliesa Anderson, the Chief Scientific Officer at
the bacterial vaccines at Pfizer and I'm going to present
the second part of a two-part series that discusses the importance of
vaccines in reducing antibiotic exposure and preventing antimicrobial resistance.
0:20
In this part of the lecture,
I will review the vaccines that are under
development that have the potential to reduce AMR.
The global mobilization actions about how to use vaccines against AMR,
barriers to maximizing licensed vaccine use,
and also efforts towards better utilization of vaccines against AMR.
0:45
In this first section,
I will review the vaccines that are in development
that can contribute towards reducing AMR.
It'll be divided into two sections.
The first, vaccines are in late-stage clinical development,
and then the second will cover vaccines that are in early stage research.
1:08
Clostridioides difficile infection, also known as CDI,
is a significant unmet medical need.
Its caused by a gram-positive bacteria called clostridium difficile or
C. difficile and it expresses toxins that causes severe diarrhea.
Often people catch this disease because they've taken
antibiotics and the antibiotics kill the bacteria in their gut that is
normally there and it helps the clostridioides difficile from
overtaking and growing well and producing the toxins that cause the disease.
In the US, there are nearly quarter of a million hospital of
associated cases of CDI every year with over 12 and a half thousands deaths.
The CDC considers Clostridium difficile infections
as hazard level urgent that is associated
with high levels of untreatable or hard to treat disease
because even though the bacteria may be susceptible to some antibiotics,
the fact that it causes and produces spores makes the antibiotics much harder to work.
Currently, there is no vaccine to prevent either the initial case of C. difficile
or the recurrent cases that occur because of
the fact that the spores then germinate to cause disease.